MedWatch

Lundbeck’s alcohol pill hits speed bump

The Danish Health and Medicines Authority has turned down Lundbeck’s appeal for general reimbursement for its alcohol pill. The company says it will not impact sales, while an analyst points out that Lundbeck has work to do to convince medicines authorities across Europe.

Foto: Lundbeck / PR

Danish patients set to receive treatment with Lundbeck’s pill against alcohol addiction, Selincro, will not automatically receive reimbursements for the drug.

Based on recommendations from the Reimbursement Committee, the Danish Health and Medicines Authorities has decided against giving general reimbursement for the drug as a therapy for alcohol dependence. The drug also failed to win general conditional reimbursement for certain diseases or patient groups.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier